HUE061100T2 - Adenovírus hõinaktiválásának módszerei - Google Patents

Adenovírus hõinaktiválásának módszerei

Info

Publication number
HUE061100T2
HUE061100T2 HUE17776462A HUE17776462A HUE061100T2 HU E061100 T2 HUE061100 T2 HU E061100T2 HU E17776462 A HUE17776462 A HU E17776462A HU E17776462 A HUE17776462 A HU E17776462A HU E061100 T2 HUE061100 T2 HU E061100T2
Authority
HU
Hungary
Prior art keywords
adenovirus
methods
heat inactivation
inactivation
heat
Prior art date
Application number
HUE17776462A
Other languages
English (en)
Inventor
Christopher Morrison
James Maratt
Original Assignee
Ultragenyx Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ultragenyx Pharmaceutical Inc filed Critical Ultragenyx Pharmaceutical Inc
Publication of HUE061100T2 publication Critical patent/HUE061100T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/76Viruses; Subviral particles; Bacteriophages
    • A61K35/761Adenovirus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2523/00Culture process characterised by temperature
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10361Methods of inactivation or attenuation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151Methods of production or purification of viral material
HUE17776462A 2016-03-28 2017-03-28 Adenovírus hõinaktiválásának módszerei HUE061100T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662314116P 2016-03-28 2016-03-28

Publications (1)

Publication Number Publication Date
HUE061100T2 true HUE061100T2 (hu) 2023-05-28

Family

ID=59966403

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE17776462A HUE061100T2 (hu) 2016-03-28 2017-03-28 Adenovírus hõinaktiválásának módszerei

Country Status (18)

Country Link
US (2) US11013774B2 (hu)
EP (2) EP3436593B1 (hu)
JP (3) JP7356224B2 (hu)
KR (1) KR102389674B1 (hu)
CN (1) CN109196106A (hu)
AU (1) AU2017241777B2 (hu)
BR (1) BR112018069703A2 (hu)
CA (1) CA3018380A1 (hu)
DK (1) DK3436593T3 (hu)
ES (1) ES2938833T3 (hu)
FI (1) FI3436593T3 (hu)
HU (1) HUE061100T2 (hu)
IL (1) IL261914B2 (hu)
LT (1) LT3436593T (hu)
PL (1) PL3436593T3 (hu)
PT (1) PT3436593T (hu)
SG (1) SG11201808183PA (hu)
WO (1) WO2017172772A1 (hu)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017005834A (es) 2014-11-05 2017-11-17 Voyager Therapeutics Inc Polinucleotidos aad para el tratamiento de la enfermedad de parkinson.
AU2015346162B2 (en) 2014-11-14 2022-02-10 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
CN112375760A (zh) 2014-11-14 2021-02-19 沃雅戈治疗公司 调节性多核苷酸
WO2016094783A1 (en) 2014-12-12 2016-06-16 Voyager Therapeutics, Inc. Compositions and methods for the production of scaav
SG11201809699XA (en) 2016-05-18 2018-12-28 Voyager Therapeutics Inc Modulatory polynucleotides
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
DK3898981T3 (da) 2018-12-18 2024-01-22 Ultragenyx Pharmaceutical Inc Fremgangsmåder og sammensætninger til behandling af glykogenlagringssygdomme
WO2023172491A1 (en) 2022-03-07 2023-09-14 Ultragenyx Pharmaceutical Inc. Modified batch aav production systems and methods

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5387484A (en) 1992-07-07 1995-02-07 International Business Machines Corporation Two-sided mask for patterning of materials with electromagnetic radiation
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
JP4216350B2 (ja) 1994-09-19 2009-01-28 大日本住友製薬株式会社 動物細胞感染用の組換えdnaウイルスベクター
US5872005A (en) 1994-11-03 1999-02-16 Cell Genesys Inc. Packaging cell lines for adeno-associated viral vectors
US6924128B2 (en) 1994-12-06 2005-08-02 Targeted Genetics Corporation Packaging cell lines for generation of high titers of recombinant AAV vectors
WO1996017947A1 (en) 1994-12-06 1996-06-13 Targeted Genetics Corporation Packaging cell lines for generation of high titers of recombinant aav vectors
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US5741683A (en) 1995-06-07 1998-04-21 The Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
US5688676A (en) 1995-06-07 1997-11-18 Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
US6027931A (en) 1995-08-03 2000-02-22 Avigen, Inc. High-efficiency AA V helper functions
ES2099678B1 (es) * 1995-11-03 1998-02-16 Grifols Grupo Sa Procedimiento para la inactivacion de virus en proteinas.
US6004797A (en) 1995-11-09 1999-12-21 Avigen, Inc. Adenovirus helper-free recombinant AAV Virion production
JP2001506133A (ja) 1996-12-18 2001-05-15 ターゲティッド ジェネティクス コーポレイション 組換えaavベクターの産生における使用のための、aavスプリット−パッケージング遺伝子およびこのような遺伝子を含む細胞株
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6995006B2 (en) 1997-09-05 2006-02-07 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
CA2303768C (en) 1997-09-19 2009-11-24 The Trustees Of The University Of Pennsylvania Methods and vector constructs useful for production of recombinant aav
IT1297074B1 (it) 1997-11-21 1999-08-03 Angeletti P Ist Richerche Bio Forme ormone-dipendenti delle proteine rep del virus adeno-associato (aav-2), sequenze di dna codificanti per esse, vettori che le
JP2003528029A (ja) * 1998-08-14 2003-09-24 アヴェンティス ファーマシューティカルズ インコーポレイテッド 遺伝子治療用のアデノウイルス配合物
AU764130B2 (en) 1998-10-27 2003-08-14 Crucell Holland B.V. Improved AAV vector production
DE19905501B4 (de) 1999-02-10 2005-05-19 MediGene AG, Gesellschaft für molekularbiologische Kardiologie und Onkologie Verfahren zur Herstellung eines rekombinanten Adeno-assoziierten Virus, geeignete Mittel hierzu sowie Verwendung zur Herstellung eines Arzneimittels
MXPA01010124A (es) * 1999-04-09 2002-06-26 Aventis Pharma Sa Composiciones destinada a la conservacion de adenovirus recombinantes infecciosos.
US20040235173A1 (en) 2000-07-03 2004-11-25 Gala Design, Inc. Production of host cells containing multiple integrating vectors by serial transduction
DE10061533B4 (de) 2000-12-11 2006-05-04 Amphenol-Tuchel Electronics Gmbh Selbsttragende Kontaktfeder, insbesondere für einen Smartcard-Connector
US7271002B2 (en) 2001-11-09 2007-09-18 United States Of America, Represented By The Secretary, Department Of Health And Human Services Production of adeno-associated virus in insect cells
US6723551B2 (en) 2001-11-09 2004-04-20 The United States Of America As Represented By The Department Of Health And Human Services Production of adeno-associated virus in insect cells
CA2369985A1 (en) 2002-01-18 2003-07-18 Duke University Generation of recombinant adeno-associated viral vectors by a complete adenovirus-mediated approach
WO2004075861A2 (en) 2003-02-26 2004-09-10 Children's Hospital, Inc. Recombinant adeno-associated virus production
BRPI0511764B8 (pt) 2004-06-01 2021-05-25 Avigen Inc método de prevenção de agregação de vírions de vírus adeno-associado recombinante (raav) em uma preparação purificada de virions raav
US7195394B2 (en) 2004-07-19 2007-03-27 Vijay Singh Method for resonant wave mixing in closed containers
US8980247B2 (en) 2004-10-21 2015-03-17 The Penn State Research Foundation Parvovirus methods and compositions for killing neoplastic cells
AU2006304997B2 (en) 2005-10-20 2012-03-01 Uniqure Ip B.V. Improved AAV vectors produced in insect cells
US9254318B2 (en) * 2006-03-31 2016-02-09 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines
ES2785223T3 (es) 2006-06-21 2020-10-06 Uniqure Ip Bv Células de insecto para la producción de vectores de AAV
GB0706638D0 (en) 2007-04-04 2007-05-16 Mbda Uk Ltd A high-dielectric material
US8580755B2 (en) 2008-02-19 2013-11-12 University Of Rochester Methods and compositions for treating inflammatory conditions
CA2742151A1 (en) 2008-11-07 2010-05-14 Intelligentnano Inc. Transfection with magnetic nanoparticles and ultrasound
HUE028341T2 (hu) * 2009-06-16 2016-12-28 Genzyme Corp Javított eljárások rekombináns AAV-vektorok tisztítására
US20140359799A1 (en) 2011-12-23 2014-12-04 Case Western Reserve University Targeted gene modification using hybrid recombinant adeno-associated virus
AU2014205604B2 (en) 2013-01-08 2020-01-02 Genzyme Corporation Use of iNOS inhibitors to increase viral yield in culture

Also Published As

Publication number Publication date
US20190083554A1 (en) 2019-03-21
LT3436593T (lt) 2023-03-10
EP3436593B1 (en) 2022-11-23
KR20180130531A (ko) 2018-12-07
EP4159867A1 (en) 2023-04-05
IL261914B1 (en) 2023-03-01
JP2019509747A (ja) 2019-04-11
KR102389674B1 (ko) 2022-04-21
US11013774B2 (en) 2021-05-25
US11944658B2 (en) 2024-04-02
CA3018380A1 (en) 2017-10-05
EP3436593A1 (en) 2019-02-06
WO2017172772A1 (en) 2017-10-05
JP7356224B2 (ja) 2023-10-04
CN109196106A (zh) 2019-01-11
DK3436593T3 (da) 2023-02-20
FI3436593T3 (fi) 2023-03-16
PT3436593T (pt) 2023-01-31
JP2021072838A (ja) 2021-05-13
IL261914A (en) 2018-10-31
PL3436593T3 (pl) 2023-03-27
EP3436593A4 (en) 2019-10-16
AU2017241777A1 (en) 2018-10-11
AU2017241777B2 (en) 2022-02-03
US20220072073A1 (en) 2022-03-10
SG11201808183PA (en) 2018-10-30
BR112018069703A2 (pt) 2019-02-05
JP2022166304A (ja) 2022-11-01
IL261914B2 (en) 2023-07-01
ES2938833T3 (es) 2023-04-17

Similar Documents

Publication Publication Date Title
EP3218942A4 (en) Heating and cooling technologies
IL261914B1 (en) Methods for heat inactivation of adenovirus
HUE051924T2 (hu) Hõkezelési eljárás
PT2905346T (pt) Método de tratamento térmico
PL3122349T3 (pl) Kompozycje do leczenia samotrawienia
GB201706677D0 (en) Cooling of rotating control device
GB201416832D0 (en) Methods of treatment
HK1249866A1 (zh) 用他塞利昔布進行治療的方法
PT3112766T (pt) Controlador de equipamento de fonte de calor
PL3249329T3 (pl) Aparat do obróbki cieplnej
DK3226731T3 (da) Varmluftkogegrej
GB2525708B (en) Heating and/or cooling assembly
HUE047616T2 (hu) Hõelvezetõ
EP3333525A4 (en) Heat treatment apparatus
EP3333526A4 (en) HEAT TREATMENT DEVICE
EP3249330A4 (en) Heat treatment device
EP3138930A4 (en) Cooling device and multi-chamber heat treatment device
GB2558216B (en) Method of heat treatment
GB201518848D0 (en) Thermal treatment device
GB201412010D0 (en) Treatment of hypertransaminasemia
GB201512139D0 (en) Methods of treatment
SG11201604943SA (en) Radiant cooling and heating apparatus
GB201609455D0 (en) Thermal reduction therapy
TWM533492U (en) Improved structure of heat pad
GB2525963B (en) Apparatus for providing three separate functions of heating, cooling, and simultaneous heating and cooling